Tolerability and activity of chemo-free triplet combination of TGR-1202, ublituximab, and ibrutinib in patients with advanced CLL and NHL By admin / 06/05/2017
Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE Phase 3 study By admin / 06/03/2017
Rapid and Robust B Cell Depletion in Preliminary Results of a Phase 2 Study of Ublituximab, Novel Glycoengineered Anti-CD20 Mab, RMS Patients By admin / 05/26/2017
TGR-1202– A novel PI3K-delta inhibitor that differentially regulates T cells in CLL By admin / 05/15/2017
TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL: Updated Results of a Multicenter Phase I/Ib Study By admin / 05/15/2017
Preliminary results of Phase 2 Multicenter Study of Ublituximab (UTX), a novel glycoengineered anti-CD20 monoclonal antibody (mAb), in patients with relapsing forms of Multiple Sclerosis (RMS) demonstrates rapid and robust B cell depletion By admin / 04/28/2017
KI intolerance study: A phase 2 study to assess the safety and efficacy of TGR-1202 in pts with chronic lymphocytic leukemia (CLL) who are intolerant to prior BTK or PI3K-delta inhibitor therapy By admin / 03/05/2017
A phase 1/2 trial of ublituximab, a novel, glycoengineered anti-CD20 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma or chronic lymphocytic leukaemia previously exposed to rituximab By admin / 12/16/2016
TGR-1202 in Combination with Ibrutinib in Patients with Relapsed or Refractory CLL or MCL: Preliminary Results of a Multicenter Phase I/Ib Study. By admin / 12/05/2016
